U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
109281
Substance Class Protein
Created
by admin
on Sat Jun 26 16:51:35 UTC 2021
Edited
by admin
on Sat Jun 26 16:51:35 UTC 2021
Protein Type RECEPTOR
Protein Sub Type REUPTAKE RECEPTOR
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
CJZ26L1EGI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM-DEPENDENT SEROTONIN TRANSPORTER
Common Name English
5HTT
Common Name English
SERT
Common Name English
SOLUTE CARRIER FAMILY 6 MEMBER 4
Common Name English
SLC6A4
Common Name English
HTT
Common Name English
SEROTONIN REUPTAKE TRANSPORTER
Common Name English
5HT TRANSPORTER
Common Name English
Code System Code Type Description
FDA UNII
CJZ26L1EGI
Created by admin on Sat Jun 26 16:51:39 UTC 2021 , Edited by admin on Sat Jun 26 16:51:39 UTC 2021
PRIMARY
From To
1_200 1_209
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_208
N 1_217
Related Record Type Details
Structure of PAROXETINE
INHIBITOR -> TARGET
Structure of FLUOXETINE
INHIBITOR -> TARGET
Structure of WF-23
INHIBITOR -> TARGET
Structure of PSEUDOEPHEDRINE
INHIBITOR -> TARGET
Structure of 2'-HYDROXYCOCAINE
LIGAND->TRANSPORTER
Structure of NIRAPARIB
INHIBITOR -> TARGET
IN-VITRO
IC50
Structure of LUMATEPERONE
ANTAGONIST->TARGET
Ki
Structure of CTP-347
INHIBITOR -> TARGET
Structure of AMITRIPTYLINE
INHIBITOR -> TARGET
Structure of VENLAFAXINE
INHIBITOR -> TARGET
IC50
Structure of TRAMADOL, (+)-
INHIBITOR -> TARGET
Structure of 403U76 FREE BASE
INHIBITOR -> TARGET
Structure of TRAMADOL
INHIBITOR -> TARGET
(+)-Tramadol inhibits serotonin reuptake
Structure of FENFLURAMINE
SUBSTRATE -> TRANSPORTER
STIMULATES SEROTONIN RELEASE.
Structure of 2C-B-AMINOREX
SUBSTRATE -> TRANSPORTER
Our data show that drugs known or suspected to increase the risk of PPH (eg, aminorex, fenfluramine, and chlorphentermine) are 5-HT transporter substrates, whereas drugs that have not been shown to increase the risk of PPH are less potent in this regard.
Structure of DULOXETINE
INHIBITOR -> TARGET
Structure of SERTRALINE
INHIBITOR -> TARGET
Structure of CITALOPRAM
INHIBITOR -> TARGET
Structure of LITOXETINE
INHIBITOR -> TARGET
Structure of PPPA
INHIBITOR -> TRANSPORTER
Structure of ESCITALOPRAM
INHIBITOR -> TARGET
Structure of VORTIOXETINE
INHIBITOR -> TARGET
Structure of IMIPRAMINE
INHIBITOR -> TARGET
Structure of N-METHYL-PPPA
INHIBITOR -> TRANSPORTER
Structure of FLUVOXAMINE
INHIBITOR -> TARGET
Kd
Structure of RTI-353
INHIBITOR -> TARGET
Structure of IP-2018
INHIBITOR -> TARGET
Structure of DASB
LIGAND->BINDER
Structure of PAROXETINE
INHIBITOR -> TARGET
Structure of DASB C-11
TARGET->RADIOLIGAND
Structure of RTI-112
INHIBITOR -> TRANSPORTER
IN-VITRO
Structure of AFM C-11
RADIOLIGAND->TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966